WHAT IS CLAIMED IS:

1. A method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an agonist or antagonist of DCRS5 (SEQ ID NOs:1 or 2) or of p19 (SEQ ID NOs:5 or 6), wherein the disorder comprises:

a) rheumatoid arthritis;

b) asthma or allergy;

c) chronic obstructive pulmonary disorder (COPD);

d) an interstitial lung disorder;

e) an inflammatory bowel disorder (IBD); or

f) an inflammatory skin disorder.

2. The method of Claim 1, wherein the skin disorder is:

a) psoriasis; or

b) atopic dermatitis.

3. The method of Claim 1, wherein the IBD is:

a) Crohn's disease; or

b) ulcerative colitis.

4. The method of Claim 1, wherein the interstitial lung disorder is:

a) idiopathic pulmonary fibrosis;

b) eosinophilic granuloma; or

c) hypersensitivity pneumonitis.

5. The method of Claim 1, wherein the antagonist comprises a binding composition derived from the antigen binding site of an antibody that specifically binds to:

a) DCRS5 (SEQ ID NO:2); or

b) p19 (SEQ ID NO:6).

6. The method of Claim 5, wherein the binding composition comprises:

a) a polyclonal antibody;

b) a monoclonal antibody;

c) a humanized antibody; or

d) an Fab, Fv, or $F(ab')_2$ fragment.

7. The method of Claim 1, wherein the agonist comprises:

a) DCRS5 (SEQ ID NO:2); or

b) p19 (SEQ ID NO:6).

8. The method of Claim 1, wherein the agonist or antagonist comprises a nucleic acid.

9. The method of Claim 8, wherein the antagonist comprises:

a) an antisense nucleic acid; or

b) an RNA interference nucleic acid.

10. A method of diagnosing a physiological disorder comprising contacting a binding composition that specifically binds to DCRS5 (SEQ ID NOs:1 or 2), or to p19 (SEQ ID NOs:5 or 6), to a sample derived from a test subject experiencing:

a) rheumatoid arthritis;

b) asthma or allergy;

c) chronic obstructive pulmonary disorder (COPD);

d) an interstitial lung disorder;

e) inflammatory bowel disorder (IBD); or

f) an inflammatory skin disorder.

11. The method of Claim 10, further comprising:

a) contacting the binding composition to a sample derived from a control subject or control sample; and

b) comparing the binding found with the test subject with the binding found with the control subject or control sample.

12. The method of Claim 10, wherein the binding composition comprises:
    a) a polyclonal antibody;
    b) a monoclonal antibody;
    c) a humanized antibody;
    d) an Fab, Fv, or $F(ab')_2$ fragment;
    e) a nucleic acid; or
    f) a detectable label.

13. The method of Claim 12, wherein the nucleic acid comprises:
    a) a probe or primer; or
    b) a molecular beacon.

14. The method of Claim 10, wherein the sample is derived from a human cell, tissue, or biological fluid.

15. The method of Claim 10, wherein the skin disorder is:
    a) psoriasis; or
    b) atopic dermatitis.

16. The method of Claim 10, wherein the IBD is:
    a) Crohn's disease; or
    b) ulcerative colitis.

17. The method of Claim 10, wherein the interstitial lung disorder is:
    a) idiopathic pulmonary fibrosis;
    b) eosinophilic granuloma; or
    c) hypersensitivity pneumonitis.